Jinxin Xu

Jinxin Xu

Auto-generated profile, based on publicly available information

Jinxin Xu

State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
XCXiaoxin Chen
Xiaoxin Chen
XHXiaodong Huang
Xiaodong Huang
QMQinhai Ma
Qinhai Ma
PKPetr Kuzmič
Petr Kuzmič
BZBiao Zhou
Biao Zhou
ZYZifeng Yang
Zifeng Yang
Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still needed, particularly for individuals in whom vaccines are less effective, such as the immunocompromised, to prevent severe COVID-19. Here we report an α-ketoamide-based peptidomimetic inhibitor of the SARS-CoV-2 main protease (M pro ), designated RAY1216. Enzyme inhibition kinetic analysis shows that RAY1216 has an inhibition constant of 8.4 nM and suggests that it dissociates about 12 times slower from M pro compared with nirmatrelvir. The crystal structure of the SARS-CoV-2 M pro :RAY1216 complex shows that RAY1216 covalently binds to the catalytic Cys145 through the α-ketoamide group. In vitro and using human ACE2 transgenic mouse models, RAY1216 shows antiviral activities against SARS-CoV-2 variants comparable to those of nirmatrelvir. It also shows improved pharmacokinetics in mice and rats, suggesting that RAY1216 could be used without ritonavir, which is co-administered with nirmatrelvir. RAY1216 has been approved as a single-component drug named ‘leritrelvir’ for COVID-19 treatment in China.

1 May 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YWYou Wu
You Wu
TXTingting Xu
Tingting Xu
JLJinsong Liu
Jinsong Liu
Ke DingKe Ding
Ke Ding
JXJinxin Xu
Jinxin Xu

8 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WBWenjing Bai
Wenjing Bai
JXJinxin Xu
Jinxin Xu
WGWenbin Gu
Wenbin Gu
DWDanyang Wang
Danyang Wang
YCYing Cui
Ying Cui
XKXiangqian Kong
Xiangqian Kong
UHRF1 maintains DNA methylation by recruiting DNA methyltransferases to chromatin. In mouse, these dynamics are potently antagonized by a natural UHRF1 inhibitory protein STELLA, while the comparable effects of its human ortholog are insufficiently characterized, especially in cancer cells. Herein, we demonstrate that human STELLA (hSTELLA) is inadequate, while mouse STELLA (mSTELLA) is fully proficient in inhibiting the abnormal DNA methylation and oncogenic functions of UHRF1 in human cancer cells. Structural studies reveal a region of low sequence homology between these STELLA orthologs that allows mSTELLA but not hSTELLA to bind tightly and cooperatively to the essential histone-binding, linked tandem Tudor domain and plant homeodomain (TTD-PHD) of UHRF1, thus mediating ortholog-specific UHRF1 inhibition. For translating these findings to cancer therapy, we use a lipid nanoparticle (LNP)-mediated mRNA delivery approach in which the short mSTELLA, but not hSTELLA regions are required to reverse cancer-specific DNA hypermethylation and impair colorectal cancer tumorigenicity.

Verified
Journal Article
Open access
PDF file
DLDongming Lan
Dongming Lan
QWQian Wang
Qian Wang
JXJinxin Xu
Jinxin Xu
PZPengfei Zhou
Pengfei Zhou
BYBo Yang
Bo Yang
YWYonghua Wang
Yonghua Wang
Thermostability and substrate specificity are important characteristics of enzymes for industrial application, which can be improved by protein engineering. SMG1 lipase from Malassezia globosa is a mono- and diacylglycerol lipase (MDL) that shows activity toward mono- and diacylglycerols, but no activity toward triacylglycerols. SMG1 lipase is considered a potential biocatalyst applied in oil/fat modification and its crystal structure revealed that an interesting residue-Asn277 may contribute to stabilize loop 273–278 and the 3104 helix which are important to enzyme characterization. In this study, to explore its role in affecting the stability and catalytic activity, mutagenesis of N277 with Asp (D), Val (V), Leu (L) and Phe (F) was conducted. Circular dichroism (CD) spectral analysis and half-life measurement showed that the N277D mutant has better thermostability. The melting temperature and half-life of the N277D mutant were 56.6 °C and 187 min, respectively, while that was 54.6 °C and 121 min for SMG1 wild type (WT). Biochemical characterization of SMG1 mutants were carried out to test whether catalytic properties were affected by mutagenesis. N277D had similar enzymatic properties as SMG1 WT, but N277F showed a different substrate selectivity profile as compared to other SMG1 mutants. Analysis of the SMG1 3D model suggested that N277D formed a salt bridge via its negative charged carboxyl group with a positively charged guanidino group of R227, which might contribute to confer N277D higher temperature stability. These findings not only provide some clues to understand the molecular basis of the lipase structure/function relationship but also lay the framework for engineering suitable MDL lipases for industrial applications.

19 August 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
JXJinxin Xu
Jinxin Xu
XTXiaowen Tang
Xiaowen Tang
YZYiguang Zhu
Yiguang Zhu
ZYZhijun Yu
Zhijun Yu
KSKai Su
Kai Su
JLJinsong Liu
Jinsong Liu
Amine compounds biosynthesis using ω-transaminases has received considerable attention in the pharmaceutical industry. However, the application of ω-transaminases was hampered by the fundamental challenge of severe by-product inhibition. Here, we report that ω-transaminase CrmG from Actinoalloteichus cyanogriseus WH1-2216-6 is insensitive to inhibition from by-product α-ketoglutarate or pyruvate. Combined with structural and QM/MM studies, we establish the detailed catalytic mechanism for CrmG. Our structural and biochemical studies reveal that the roof of the active site in PMP-bound CrmG is flexible, which will facilitate the PMP or by-product to dissociate from PMP-bound CrmG. Our results also show that amino acceptor caerulomycin M (CRM M), but not α-ketoglutarate or pyruvate, can form strong interactions with the roof of the active site in PMP-bound CrmG. Based on our results, we propose that the flexible roof of the active site in PMP-bound CrmG may facilitate CrmG to overcome inhibition from the by-product.

21 May 2017 in FEBS Letters
Verified
Journal Article
Open access
PDF file
KSKai Su
Kai Su
TXTingting Xu
Tingting Xu
ZYZhijun Yu
Zhijun Yu
JZJiabin Zhu
Jiabin Zhu
YZYulong Zhang
Yulong Zhang
JXJinxin Xu
Jinxin Xu
SNX25, a regulator of GPCR signaling‐phox‐homology (PX) domain containing sorting nexin (SNX) member, has been proposed to be involved in the lysosomal degradation of the transforming growth factor β receptor and the development of temporal lobe epilepsy. Targeting to the endosomal membranes by the specific binding of phosphorylated phosphatidylinositols (PIPs) through the PX domain is critical for the function of SNXs. However, the mechanism for SNX25‐PX targeting to the endosomes remains unclear. Here, we demonstrate that the PX domain of zebrafish SNX25 (zSNX25‐PX) is capable of binding to PI3P only in its dimeric form. We also present the crystal structure of zSNX25‐PX. Combined with biochemical experiments, we further identify a potential PI3P‐binding region and propose a novel PI‐binding model based on dimerization in the PX domain of SNXs.